Advertisement

Document › Details
Oxford Biomedica plc. (9/4/17). "Press Release: Oxford BioMedica to Present at Rodman & Renshaw Annual Global Investment Conference, New York". Oxford.
![]() |
Region | New York, NY |
Country | United States (USA) | |
![]() |
Organisation | Oxford Biomedica plc (LSE: OXB) |
Group | Oxford Biomedica (Group) | |
Organisation 2 | Rodman & Renshaw Conferences LLC | |
![]() |
Product | Rodman & Renshaw Annual Global Investment Conference 2017 New York |
Product 2 | LentiVector® technology | |
![]() |
Index term | Oxford BioMedica–Rodman & Renshaw: investor conference, 201709 supply service OBM presents at Rodman & Renshaw Global Investment Conference in NY |
Index term 2 | Oxford BioMedica–Consilium: public relations, 201604 service existent by CSC | |
![]() |
Person | Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe) |
Person 2 | Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications) | |
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York on Tuesday 12 September at 08:20 EST.
-Ends-
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries:
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
Tel: +44 (0)20 3709 5700
Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900
WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321
Record changed: 2020-06-08 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Oxford Biomedica (Group)
- [1] PhoreMost Ltd.. (11/9/20). "Press Release: PhoreMost and Oxford Biomedica Enter Gene Therapy Discovery Collaboration". Cambridge & Oxford....
- [2] Oxford BioMedica plc. (9/1/20). "Press Release: Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222". Oxford....
- [3] Oxford Biomedica plc. (6/8/20). "Press Release: Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre". Oxford....
- [4] Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford....
- [5] Oxford Biomedica plc. (3/18/20). "Press Release: Oxford BioMedica Signs License & Clinical Supply Agreement with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for LentiVector Platform for CAR-T and TCR-T Therapeutics". Oxford....
- [6] Oxford Biomedica plc. (5/28/19). "Press Release: Oxford BioMedica Announces Strategic Investment by Novo Holdings A/S". Oxford....
- [7] Oxford Biomedica plc. (3/14/19). "Press Release: Oxford Biomedica plc Preliminary Results for the Year Ended 31 December 2018". Oxford....
- [8] Oxford Biomedica plc. (3/12/19). "Press Release: Oxford Biomedica Announces R&D Collaboration with Microsoft to Improve Gene and Cell Therapy Manufacturing Using the Intelligent Cloud and Machine Learning". Oxford....
- [9] Oxford Biomedica plc. (2/7/19). "Press Release: Oxford Biomedica Provides Update on Programmes Outlicensed to Sanofi". Oxford....
- [10] Oxford Biomedica plc. (11/23/18). "Press Release: Oxford BioMedica Announces New Digital Framework Initiative to Streamline the Production of Next-generation Medicines with Cash Injection from Innovate UK". Oxford....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top